Posters

One-year results of trabecular micro-bypass stent implantation (iStent® or iStent inject®) in a real-world setting

Poster Details

First Author: J.Lake BRAZIL

Co Author(s):    R. Guedes   D. Gravina   V. Guedes   A. Chaoubah           

Abstract Details

Purpose:

Consecutive retrospective case series to evaluate the effectiveness and safety of iStent® and iStent Inject® trabecular micro-bypass stent implantation with concomitant cataract surgery or as a standalone procedure in open-angle glaucoma.

Setting:

Longitudinal data from a single surgeon at a single site in Brazil.

Methods:

Performance outcomes through 1 year included intraocular pressure (IOP); glaucoma medication burden; proportions of eyes with IOP of <18 mmHg; and proportions of eyes that were medication-free.  Safety outcomes included adverse events, secondary surgeries, and visual acuity.  This report includes 104 eyes (41 iStent, 63 iStent inject) with 1-year data, and follow-up is ongoing.  Approximately 77% of eyes had primary open-angle glaucoma, with the remaining eyes having pseudoexfoliative or pigmentary glaucoma.  Stent implantation was completed with cataract surgery in 81% of eyes.

Results:

At 1 year versus preoperative, mean IOP reduced from 16.3mmHg to 13.9mmHg (p=0.001) in iStent eyes, and from 16.3 to 12.6 mmHg (p<0.001) in iStent inject eyes (between-group comparison p=0.019).  Medication count also reduced from 1.7 to 0.5 in iStent eyes (p<0.001), and from 2.1 to 0.3 in iStent inject eyes (p<0.001).  87.2% of iStent eyes achieved IOP <18mmHg compared to 100% of iStent inject eyes. 63% of iStent eyes were medication-free at 1 year compared to 81% of iStent inject eyes. Both groups had favorable safety, with fewer adverse events observed with iStent inject than iStent.

Conclusions:

Implantation of the iStent or iStent inject either with or without cataract surgery resulted in significant reductions in IOP and medications through 1 year postoperative in this real-world study comprised of an open-angle glaucoma population.   Trends toward greater effectiveness and fewer adverse events were observed with the iStent inject device compared with the iStent device.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a competing company